source
- Lilly's Foundayo obesity pill posts $98 million Q2 sales, trails Novo's WegovyEli Lilly introduced its oral obesity treatment Foundayo after receiving FDA approval in April 2025. The drug entered the market in the second quarter of 2026, marking Lilly's first foray into an o…
- Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mountNovo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…